CAT-Trial

CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, randomized, placebo-controlled, international multicenter, phase II clinical trial.

Background and aim

To test a CGRP monoclonal antibody on the effect on pain in diabetic neuropathy .

Study design

Randomized controlled trial.

Collaborators

Steno Diabetes Center Aarhus (SDCA)
Mayo Clinic (US)

Funding

Novo Nordisk Foundation.

Project period

1 October 2023 - 1 April 2025.

Updated on 20 November 2023

Last updated: 20. November 2023

Responsible editor

Stenos webteam